Tolgabide

Tolgabide
Clinical data
ATC code	none
Legal status
Legal status	Uncontrolled;
Identifiers
	IUPAC name 4-{[(E)-(3-Chloro-5-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)(4-chlorophenyl)methyl]amino}butanamide;
CAS Number	86914-11-6
PubChem (CID)	5748792
ChemSpider	14917033
UNII	0L55QF645F
KEGG	D06181
ChEMBL	CHEMBL2104937
Chemical and physical data
Formula	C18H18Cl2N2O2
Molar mass	365.25 g/mol
3D model (Jmol)	Interactive image
	SMILES Cc1cc(cc(c1O)/C(=N/CCCC(=O)N)/c2ccc(cc2)Cl)Cl ;
	InChI InChI=1S/C18H18Cl2N2O2/c1-11-9-14(20)10-15(18(11)24)17(22-8-2-3-16(21)23)12-4-6-13(19)7-5-12/h4-7,9-10,24H,2-3,8H2,1H3,(H2,21,23)/b22-17+ ; Key:AOAFGVWKONLQRN-OQKWZONESA-N ;

Tolgabide INN (SL-81.0142) is a drug which was patented by Synthélabo as an anticonvulsant but was never marketed.^[1] It is an analogue of progabide and acts similarly to it as a prodrug of GABA, and therefore as an indirect agonist of the GABA receptors.^[1]^[2]

Synthesis[edit]

Tolgabide synthesis: J. P. Kaplan, Synthélabo, DE 3242442 (1983)